Silence Therapeutics PLC Results of EGM (9399T)
July 23 2020 - 11:02AM
UK Regulatory
TIDMSLN
RNS Number : 9399T
Silence Therapeutics PLC
23 July 2020
Results of General Meeting
London, 23(rd) July 2020
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that at its General Meeting held today,
Thursday, 23(rd) July 2020, all resolutions set out in the notice
of meeting were duly passed on a poll.
The votes were as follows:
Resolution Votes % Votes against % Votes total % of ISC Votes withheld
for voted
1 - Restatement
of long term
incentive plans
(ordinary resolution) 38,168,851 98.0 772,001 2.0 38,940,852 47.0 4,276,757
----------- ----- -------------- ---- ------------ --------- ---------------
2 - Approval
of US Employee
Sub-Plan (ordinary
resolution) 38,185,627 98.1 755,225 1.9 38,940,852 47.0 4,276,757
----------- ----- -------------- ---- ------------ --------- ---------------
3 - Approval
of new articles
of association
(special resolution) 38,940,642 100 210 0 38,940,852 47.0 4,276,757
----------- ----- -------------- ---- ------------ --------- ---------------
The number of the Company's ordinary shares in issue as at the
date of the meeting was 82,826,259 ordinary shares of 5p each.
A vote withheld is not a vote in law and has not been counted in
the calculation of the proportion of votes for and against the
resolutions.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Iain Ross, Executive Chairman 6900
Dr Rob Quinn, Chief Financial Officer
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
US IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-associated proteins. Silence's proprietary
RNA chemistries and delivery systems are designed to improve the
stability of molecules and enhance effective delivery to target
cells, providing a powerful modular technology well suited to
tackle life-threatening diseases. The Company has secured high
value research and collaboration agreements with AstraZeneca,
Mallinckrodt Pharmaceuticals and Takeda. For more information,
please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMFLFEEDTIVFII
(END) Dow Jones Newswires
July 23, 2020 12:02 ET (16:02 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024